239 related articles for article (PubMed ID: 35654721)
1. Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.
Boquimpani C; Seguro FS; Magalhães GHR; Pinto ILS; Bendit I; Bortolini JAP; Pagnano KBB; Centrone R; Funke V
Hematol Transfus Cell Ther; 2022; 44(3):402-409. PubMed ID: 35654721
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
3. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26
Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M
Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536
[No Abstract] [Full Text] [Related]
4. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
5. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
7. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
8. Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.
Pavlovsky C; Abello Polo V; Pagnano K; Varela AI; Agudelo C; Bianchini M; Boquimpani C; Centrone R; Conchon M; Delgado N; Funke V; Giere I; Luise I; Meillon L; Moiraghi B; Navarro JR; Pilleux L; Prado AI; Undurraga S; Cortes J
Blood Adv; 2021 Dec; 5(23):4855-4863. PubMed ID: 34438444
[TBL] [Abstract][Full Text] [Related]
9. Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices.
Dengler J; Tesch H; Jentsch-Ullrich K; Gerhardt A; Schulte C; Lipke J; Löwe G; Kiani A
Acta Haematol; 2022; 145(6):603-610. PubMed ID: 35908542
[TBL] [Abstract][Full Text] [Related]
10. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
13. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
[TBL] [Abstract][Full Text] [Related]
14. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia.
Chen Y; Xu N; Yang Y; Liu Z; Xue M; Meng L; He Q; Chen C; Zeng Q; Zhu H; Du X; Zou J; He W; Guo J; Chen S; Yuan G; Wu H; Hong M; Cheng F; Liu B; Zhang Y; Li W
Cancer Med; 2023 Aug; 12(16):17239-17252. PubMed ID: 37409506
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
17. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
18. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
Breccia M; Foà R
Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
[TBL] [Abstract][Full Text] [Related]
19. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
Saifullah HH; Lucas CM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
